Author name: Dave Goyal

For the last four years, headlines and boardrooms obsessed over the same outdated question: “Which AI is best?” Now, that […]

Artificial intelligence is evolving rapidly, but a quiet revolution is reshaping how leaders make decisions. Most executives are familiar with

Innovation in pharmaceuticals has never been more essential, or more challenging. Scientific breakthroughs in genomics, AI-driven drug design, and personalized

AI driven commerce is undergoing a structural shift. Instead of influencing users through recommendations, autonomous agents are beginning to act

The New Frontier of Intelligence in Business As generative AI and early AGI-capable models evolve at pace, many enterprises still

The Fork in the AI Road 72% percent of tech-forward companies now use open-source AI models. Nearly half also rely

You may think the big expense in AI is training your model. It isn’t.  The real financial shock comes later

For much of the past decade, the dominant story in AI has been the rise of ever larger monolithic models.

Most executive conversations about AI begin with model selection: which foundation model, what parameter count, and which vendor. Those questions

The phrase foundation model has become shorthand for the large, general-purpose AI systems that power a wide range of applications